证券日报网讯1月22日，瑞普生物（300119）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总户数为25567户。 ...

证券日报网讯1月22日，瑞普生物（300119）在互动平台回答投资者提问时表示，未来公司将持续深耕 该领域，丰富产品矩阵，为宠物提供更多优质的健康解决方案。 ...

证券日报网讯 1月22日，瑞普生物在互动平台回答投资者提问时表示，公司应收账款按与客户签订的合 同约定回款期推进回款工作，公司已严格按照账龄分析法及单项认定法计提坏账准备，相关财务处理符 合企业会计准则要求，充分考虑了回款相关风险。具体情况请关注公司后续披露的定期报告。 （文章来源：证券日报） ...

证券日报网讯1月22日，瑞普生物（300119）在互动平台回答投资者提问时表示，喵干素为重组猫干扰 素ω(冻干型)，其主要成分为重组猫干扰素ω蛋白，主要用于猫疱疹病毒感染的治疗，可提升猫咪的抗感 染能力，属于兽用生物制品。 ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司年报预告什么时候公示？ 瑞普生物（300119.SZ）1月22日在投资者互动平台表示，公司2025年度报告已预约2026年3月31日披 露，相关信息请以公司后续在深交所官网、巨潮资讯网发布的正式公告为准。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：现在家庭对宠物陪伴特别看重，贵公司是否会推出一 些宠物保健品或者营养品，提升宠物的体质健康和营养均衡。 瑞普生物（300119.SZ）1月22日在投资者互动平台表示，公司已推出氨糖软骨素、角鲨烯辅酶 Q10等多 款宠物营养保健品，26年即将上市磷虾鱼油、益生菌等产品，可助力宠物体质提升与营养均衡，契合养 宠家庭的宠物健康养护需求。未来公司将持续深耕该领域，丰富产品矩阵，为宠物提供更多优质的健康 解决方案。 ...

Core Insights - Ruipai Pet Hospital Management Co., Ltd. submitted its listing application to the Hong Kong Stock Exchange, planning to issue approximately 250 million shares to raise funds primarily for expanding its hospital network and digital infrastructure [1][11] - The company, founded in 2012, operates 548 pet hospitals across about 70 cities in China and is recognized as the second-largest pet medical service provider in the country, uniquely achieving profitability among large national chains [1][3][11] Industry Context - The Chinese pet economy is experiencing explosive growth, with the urban consumption market exceeding 300 billion yuan, and pet medical services accounting for nearly 30% of this market [2][12] - The pet medical market is projected to grow from 36.6 billion yuan in 2024 to 139.2 billion yuan by 2035, but the industry faces challenges with a fragmented structure where over 20,000 pet hospitals exist, with only 21.1% being part of chains [2][12] - Despite the market potential, many companies, including industry leader New Ruipeng, have struggled with profitability, with cumulative losses exceeding 3.7 billion yuan over three years, highlighting the industry's reliance on capital without translating scale into profit [2][12] Company Strategy - Ruipai's listing is seen as more than a capital operation; it aims to explore a sustainable and profitable business model in a challenging industry landscape [3][13] - The company employs a unique expansion strategy combining strategic acquisitions and the VDP (Veterinary Development Partner) model, which retains original management and veterinary staff's equity to enhance integration and reduce talent loss [4][5][14][15] - As of June 2025, 78.1% of Ruipai's hospitals were acquired, allowing for rapid market penetration and stable service quality [4][14] Financial Performance - Ruipai achieved a gross margin of 24.8% in the first half of 2025, significantly higher than the industry average, and has optimized its revenue structure through a three-tier collaborative system of regional, urban, and community hospitals [5][15] - The company has shifted its focus from absolute growth to enhancing network quality and store efficiency, indicating a commitment to refined operations [5][15] Future Vision - Ruipai aims to transition from a pet hospital chain to a comprehensive health management platform for pets, leveraging digital tools to enhance customer engagement and service frequency [9][18] - The company plans to invest heavily in information technology and digital platform development to integrate services across the pet care spectrum, aspiring to create an ecosystem connecting pet owners, veterinarians, suppliers, and insurance companies [10][19] - This strategic shift is positioned to capitalize on the evolving pet economy, with the potential to redefine revenue streams beyond traditional medical services [10][19]

Core Viewpoint - The animal health sector experienced a decline of 0.65% on January 21, with Huisheng Biological leading the drop. The Shanghai Composite Index rose by 0.08%, while the Shenzhen Component Index increased by 0.7 [1] Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Shunlian Biological up by 4.20% and Huisheng Biological down by 6.19% [1][2] - The trading volume for Huisheng Biological was 419,900 shares, with a transaction value of 1.192 billion yuan, indicating significant market activity despite the decline [2] Group 2: Capital Flow - The animal health sector saw a net inflow of 9.6935 million yuan from institutional investors, while retail investors experienced a net outflow of 73.8174 million yuan, suggesting a shift in investor sentiment [2][3] - Among individual stocks, Xianfeng Holdings had a net inflow of 15.1182 million yuan from institutional investors, while Huisheng Biological saw a net outflow of 42.2249 million yuan from retail investors [3]

Investment Rating - The overall industry investment rating is "Positive" for the planting and livestock sectors, "Neutral" for forestry and aquaculture, and "II" for agricultural product processing [7][8]. Core Insights - The pig price is experiencing a seasonal rebound, with the average price at 12.78 CNY/kg, a slight increase of 0.15 CNY from the previous week. However, the mid-term outlook remains pessimistic due to ongoing market pressures [6][23]. - The livestock industry is undergoing a capacity reduction, with the number of breeding sows decreasing to 39.90 million heads, down 1.1% month-on-month. This trend is expected to continue due to low market prices, rising epidemic risks, and policy pressures [7][24]. - The chicken industry is facing high capacity levels, with prices expected to fluctuate in the mid-term. The average price for broiler chickens is currently at 3.77 CNY/kg, reflecting a slight decrease [8][25]. - The yellow chicken market is anticipated to see price increases due to low production levels, with the average price at 12.95 CNY/kg [10][27]. - The veterinary medicine sector is experiencing a price rebound for key antibiotics, with a year-on-year increase of over 20% expected [11][27]. - The seed industry is benefiting from favorable policies and the advancement of genetically modified crops, which is expected to enhance sales and pricing for quality seed companies [13][28]. - Grain prices are projected to rise in the mid-term due to reduced imports and supportive domestic policies, with corn prices currently at 2369 CNY/ton [14][29]. Summary by Sections Livestock Industry - The average price for live pigs is 12.78 CNY/kg, with a slight increase of 0.15 CNY from last week. The average price for piglets is 25.14 CNY/kg, up 0.66 CNY [6][23]. - The operating rate of large-scale slaughterhouses is 38.58%, down 1.19 percentage points from last week [6][23]. - The number of breeding sows has decreased to 39.90 million heads, down 1.1% month-on-month, indicating a trend of capacity reduction [7][24]. Chicken Industry - The average price for broiler chickens is 3.77 CNY/kg, with a slight decrease of 0.03 CNY from last week [8][25]. - The industry is at a historically high capacity level, with prices expected to remain volatile in the mid-term [9][26]. - The yellow chicken market is expected to tighten supply, with prices likely to rise due to low production levels [10][27]. Veterinary Medicine - Key antibiotic prices are rebounding, with a year-on-year increase of over 20% expected [11][27]. - The market for veterinary vaccines is also growing, with increased sales anticipated for domestically produced vaccines [12][27]. Seed and Grain Industry - The seed industry is benefiting from favorable policies and advancements in genetically modified crops, which are expected to drive sales and pricing [13][28]. - Grain prices are projected to rise due to reduced imports and supportive domestic policies, with corn prices currently at 2369 CNY/ton [14][29].